摘要
心肾综合征(CRS)是一种临床综合征,其发生发展与血流动力学改变、神经体液因素异常持续激活、炎症、氧化应激、贫血等因素密切相关。钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)作为一种临床广泛应用的新型口服降血糖药,在最近的大型临床研究中对心血管和肾脏疾病都显示出了一致的益处。因此SGLT2i有望成为改善CRS患者预后的重要治疗手段。现总结最近SGLT2i在大型临床试验中的心肾获益证据,并从CRS病理生理角度探讨其独立于降糖作用以外可能的心肾共同获益机制。
Cardiorenal syndrome(CRS)is a clinical syndrome characterized by hemodynamic changes,abnormal continuous activation of neurohumoral factors,inflammation,oxidative stress and anemia.Recent large clinical studies have consistently shown that sodium-glucose co-transporter 2 inhibitor(SGLT2i),a novel oral hypoglycemic agent,provides benefits for both cardiovascular and kidney diseases.Therefore,SGLT2i expected to be an important treatment to improve the prognosis of patients with CRS.This article aims to summarize the recent evidence of cardiorenal benefit from SGLT2i in large clinical trials and explore the potential mechanism of this benefit in treating cardiorenal syndrome,independent of its hypoglycemic effect,from the pathophysiological perspective.
作者
张严
宋可欣
姚朱华
ZHANG Yan;SONG Kexin;YAO Zhuhua(Graduate School of Tianjin Medical University,Tianjin 300070,China;Tianjin Union Medical Center,Tianjin Medical University,Tianjin 300121,China;Graduate School of Hebei Medical University,Shijiazhuang 050017,Hebei,China;Department of Cardiology,Hebei General Hospital,Shijiazhuang 050051,Hebei,China;The Institute of Translational Medicine,Tianjin Union Medical Center of Nankai University,Tianjin 300121,China)
出处
《心血管病学进展》
CAS
2024年第5期389-391,396,共4页
Advances in Cardiovascular Diseases
基金
天津市卫生健康科技项目(ZC20080)。
关键词
心肾综合征
心血管疾病
肾脏疾病
钠-葡萄糖共转运蛋白2抑制剂
心肾保护
Cardiorenal syndrome
Cardiovascular disease
Kidney disease
Sodium-glucose co-transporter 2 inhibitor
Cardiorenal protection
